Clement Agyemang

Clement Agyemang

Auto-generated profile, based on publicly available information

Clement Agyemang

The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology Houston, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Many of the >130 World Health Organization–defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2/7/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities. Significance: Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.

17 June 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Figure S2. Heatmap of the CDK2, CDK7, and CDK9 expression in sarcoma cells from the Cancer Cell Line Encyclopedia (CCLE) database.

31 July 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Figure S1. Unsupervised hierarchical clustering of drug AUC values after filtering for min = 0.2 (blue) and max = 0.7 (red).

31 July 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Figure S3. Loading control for the Western blots in Figure 3 of GAPDH for each of the myxoid liposarcoma cell lines: DDL-221, MLS-401-91, and MLS-1765-92.

17 June 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).

17 June 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal